![Meng Qi Chen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ms. Mang Qi Chen, CICPA & ACCA, Financial Controller.
Prior to joining BioVeda China, Ms. Chen was Auditing Manager with Price Waterhouse Coopers, Shanghai, China office.
She had five years of financial auditing experience with PWC, managing financial institution’s audits, including auditing private equity funds (US GAAP).
Ms. Chen was responsible for audits of four venture and private equity funds in China, which included Softbank China, DT Capital, and BioVeda China Fund I.
She also participated in audits for the Bank of Communication (IPO), JP Morgan Tianjin, Shanghai, OCBC Shanghai, Chengdu and Xiamen, BOA Shanghai, Barkley Shanghai, China Life Insurance, AXA-minmetals Life, and AIA Barclays.
Ms. Chen received her Bachelor of International Accounting, Shanghai University of Finance & Economics.
| Sociétés | Poste | Début |
|---|---|---|
Shanghai Bioveda Investment Management Consulting Co. Ltd.
 Shanghai Bioveda Investment Management Consulting Co. Ltd. Investment ManagersFinance BioVeda China is an active manager which invests in innovative Chinese companies exclusively in the life science and healthcare sectors, including pharmaceuticals, biotech, medtech, healthcare services and industrial biotech. They invest in companies from series A to mezzanine stage, invest only in early-stage which have breakthrough platform technology and huge market potential. The firm seeks to invest in companies with a dominant market position, rapid growth potential, a strong management team, proprietary technologies, significant competitive advantages, a business model with clear exit strategy or survivability and sale, merger or listing potential within three to five years. BioVeda partners with their investee companies, providing them with strategic assistance to realize growth. | Comptroller/Controller/Auditor | 01/01/2007 |
Edmond De Rothschild Investment Partners (Shanghai) Ltd.
 Edmond De Rothschild Investment Partners (Shanghai) Ltd. Investment ManagersFinance Acts as an alternative investment manager | Directeur/Membre du Conseil | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 2 |
|---|---|
Shanghai Bioveda Investment Management Consulting Co. Ltd.
Shanghai Bioveda Investment Management Consulting Co. Ltd. Investment ManagersFinance BioVeda China is an active manager which invests in innovative Chinese companies exclusively in the life science and healthcare sectors, including pharmaceuticals, biotech, medtech, healthcare services and industrial biotech. They invest in companies from series A to mezzanine stage, invest only in early-stage which have breakthrough platform technology and huge market potential. The firm seeks to invest in companies with a dominant market position, rapid growth potential, a strong management team, proprietary technologies, significant competitive advantages, a business model with clear exit strategy or survivability and sale, merger or listing potential within three to five years. BioVeda partners with their investee companies, providing them with strategic assistance to realize growth. | Finance |
Edmond De Rothschild Investment Partners (Shanghai) Ltd.
Edmond De Rothschild Investment Partners (Shanghai) Ltd. Investment ManagersFinance Acts as an alternative investment manager | Finance |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
